These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34128042)

  • 21. Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece.
    Gourzoulidis G; Koulentaki M; Koumarianou A; Samadas E; Androulakis N; Xynogalos S; Papakotoulas P; Boukovinas I; Karamouzis M; Souglakos J; Chotzagiannoglou V; Beletsi A; Kourlaba G
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):259-269. PubMed ID: 33900864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.
    Giuliani J; Mantoan B; Mangiola D; Muraro M; Napoli G; Tommasi M; Fiorica F; Mandarà M
    Clin Colorectal Cancer; 2024 Mar; 23(1):1-3. PubMed ID: 37932152
    [No Abstract]   [Full Text] [Related]  

  • 23. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
    Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
    Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
    BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
    Narita Y; Shoji H; Kawai S; Mizukami T; Nakamura M; Moriwaki T; Yamanaka T; Sunakawa Y; Kawakami H; Nishina T; Misumi T; Muro K
    Future Oncol; 2021 Mar; 17(8):869-875. PubMed ID: 32954810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.
    Michl GM; Vogt FM; Nouriani A; Ladurner R; Kremer M; Reisländer T; Michl M
    Chemotherapy; 2024; 69(1):27-34. PubMed ID: 37336201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
    Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
    J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
    Gourzoulidis G; Maniadakis N; Petrakis D; Souglakos J; Pentheroudakis G; Kourlaba G
    J Comp Eff Res; 2019 Feb; 8(3):133-142. PubMed ID: 30547679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
    Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
    Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
    Zaniboni A; Barone CA; Banzi MC; Bergamo F; Blasi L; Bordonaro R; Bartolomeo MD; Costanzo FD; Frassineti GL; Garufi C; Giuliani F; Latiano TP; Martinelli E; Personeni N; Racca P; Tamburini E; Tonini G; Besse MG; Spione M; Falcone A
    Future Oncol; 2021 Jun; 17(18):2315-2324. PubMed ID: 33663264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
    Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH
    ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
    Giuliani J; Bonetti A
    Eur J Cancer; 2020 Oct; 138():77-79. PubMed ID: 32871525
    [No Abstract]   [Full Text] [Related]  

  • 37. Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.
    Ghidini M; Hochster H; Doi T; Van Cutsem E; Makris L; Takahashi O; Benhadji KA; Mansoor W
    Gastric Cancer; 2023 Jul; 26(4):626-637. PubMed ID: 37106214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 39. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
    Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
    Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.
    Bordonaro R; Calvo A; Auriemma A; Hollebecque A; Rubovszky G; Saunders MP; Pápai Z; Prager G; Stein A; André T; Argilés G; Cubillo A; Dahan L; Edeline J; Leger C; Cattan V; Fougeray R; Amellal N; Tabernero J
    ESMO Open; 2021 Oct; 6(5):100270. PubMed ID: 34547581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.